Company Information
USD
5.985
- (-1.6%)
NASDAQ:FOLD, AMICUS THERAPEUTICS, INC.
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Address
47 Hulfish Street
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Michael A Kelly
Director
Mr. Burke W. Whitman
Director
Mr. Craig A. Wheeler
Director
Ms. Margaret G. McGlynn
Director
Mr. Glenn P. Sblendorio
Director
Mr. Bradley L. Campbell
CEO/Director/President
Mr. Michael G. Raab
Chairman of the Board/Director
Mr. Simon Nicolas Reade Harford
CFO
Ms. Daphne E. Quimi
Senior VP, Divisional
Ms. Lynn Dorsey Bleil
Director
Dr. Eiry W. Roberts, M.D.
Director
Ms. Samantha Prout
Chief Accounting Officer/Controller
Ms. Ellen S. Rosenberg
Chief Legal Officer/General Counsel/Secretary
Mr. David M. Clark
Other Executive Officer
Mr. Jeffrey P. Castelli
Other Executive Officer
Ownership
Institution Holdings
Vanguard Group Inc
28,492,486 (9.705%)
Perceptive Advisors LLC
28,057,456 (9.557%)
venBio Select Advisor LLC
27,400,000 (9.333%)
BlackRock Inc
22,988,139 (7.830%)
JPMorgan Chase & Co
17,848,531 (6.079%)
Redmile Group, LLC
16,944,621 (5.771%)
Wellington Management Company LLP
15,190,024 (5.174%)
Wellington Management Group, LLP
15,190,024 (5.174%)
Morgan Stanley - Brokerage Accounts
13,327,897 (4.540%)
State Street Corporation
13,163,085 (4.483%)
Individual Holdings
Mr. Bradley L. Campbell
871,219 (0.295%)
Ms. Daphne E. Quimi
398,532 (0.142%)
Ms. Ellen S. Rosenberg
367,654 (0.125%)
Mr. David Michael Clark
253,664 (0.086%)
Mr. Simon Nicolas Reade Harford
164,365 (0.056%)
Mr. Allsop David
50,000 (0.052%)
Mr. Glenn P. Sblendorio
95,303 (0.034%)
Mr. Burke W. Whitman
86,337 (0.030%)
Ms. Lynn Dorsey Bleil
81,680 (0.029%)
Ms. Samantha Prout
80,953 (0.028%)
Funds Holdings
Vanguard Total Stock Market Index Fund
9,520,602 (3.223%)
Vanguard US Total Market Shares ETF
9,520,602 (3.223%)
Vanguard Small Cap Index
7,488,405 (2.535%)
SPDR® S&P Biotech ETF
7,468,496 (2.528%)
iShares Russell 2000 ETF
6,917,950 (2.342%)
Delaware Small Cap Core Fund
5,298,797 (1.794%)
Vanguard Small Cap Growth Index Fund
4,181,134 (1.416%)
American Century Heritage Fund
4,090,973 (1.385%)
American Century US Opport. Mid Cap Gr
4,090,973 (1.385%)
Vanguard Institutional Extnd Mkt Idx Tr
3,938,578 (1.333%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
